Uncovering the genetic architecture of multiple sclerosis

CONTINUUM Lifelong Learning in Neurology

Volumn 16, Issue 5, 2010, Pages 147-165

  Esposito, Federica ^a   De Jager, Philip L ^a  

^a Merck Serono ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD2 ANTIGEN; CD40 ANTIGEN; CD6 ANTIGEN; CELL CYCLE PROTEIN 37; CYCLIN DEPENDENT KINASE 4; HLA A ANTIGEN; HLA A3 ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR15 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 3; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 12P35; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; LYMPHOTOXIN; MESSENGER RNA; PROTEIN KINASE TYK2; STAT PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELIAC DISEASE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CROHN DISEASE; DISEASE PREDISPOSITION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC RISK; GENETICS; GENOMICS; GRAVES DISEASE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; PROTEOMICS; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TRANSCRIPTOMICS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

EID: 78650744485     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000389939.15155.eb     Document Type: Article

References (65)

1. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273(5281):1516-1517.
2. Sadovnick AD, Baird PA, Ward RH. Multiple sclerosis: Updated risks for relatives. Am J Med Genet 1988;29(3):533-541.
3. Ebers GC, Sadovnick AD, Risch NJ; Canadian Collaborative Study Group. A genetic basis for familial aggregation in multiple sclerosis. Nature 1995;377(6545):150-151.
4. Sadovnick AD, Ebers GC, Dyment DA, et al. Canadian Collaborative Study Group. Evidence for genetic basis of multiple sclerosis. Lancet 1996;347(9017):1728-1730.
5. Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet 1972;1(7762):1240-1241.
6. Naito S, Namerow N, Mickey MR, Terasaki PI. Multiple sclerosis: Association with HL-A3. Tissue Antigens 1972;2(1):1-4.
7. Jersild C, Fog T, Hansen GS, et al. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973;2(7840):1221-1225.
8. Hauser SL, Fleischnick E, Weiner HL, et al. Extended major histocompatibility complex haplotypes in patients with multiple sclerosis. Neurology 1989;39(2 pt 1):275-277.
9. Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004;74(1):160-167.
10. Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006;15(18):2813-2824.
11. Marrosu MG, Murru MR, Costa G, et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am J Hum Genet 1997;61(2):454-457.
12. Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: A review and pooled analysis. PLoS Genet 2008;4(4):e1000024.
13. Brynedal B, Duvefelt K, Jonasdottir G, et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2007;2(7):e664.
14. Fogdell-Hahn A, Ligers A, Gronning M, et al. Multiple sclerosis: A modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000;55(2):140-148.
15. Bergamaschi L, Leone MA, Fasano ME, et al. HLA-class I markers and multiple sclerosis susceptibility in the Italian population. Genes Immun 2010;11(2):173-180.
16. Yeo TW, De Jager PL, Gregory SG, et al. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol 2007;61(3):228-236.
17. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009;41(7):776-782.
18. International MHC and Autoimmunity Genetics Network (IMAGEN), Rioux JD, Goyette P, et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A 2009;106(44):18680-18685.
19. Haines JL, Terwedow HA, Burgess K, et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum Mol Genet 1998;7(8):1229-1234.
20. Sawcer S, Ban M, Maranian M, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005;77(3):454-467.
21. Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. Nat Rev Genet 2004;5(12):889-899.
22. International Multiple Sclerosis Genetics Consortium (IMSGC), Hafler DA, Compston A, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357(9):851-862.
23. Lundmark F, Duvefelt K, Iacobaeus E, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007;39(9): 1108-1113.
24. Gregory SG, Schmidt S, Seth P, et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007;39(9):1083-1091.
25. International Multiple Sclerosis Genetics Consortium (IMSGC). Refining genetic associations in multiple sclerosis. Lancet Neurol 2008;7(7):567-569.
26. Akashi K, Kondo M, von Freeden-Jeffry U, et al. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 1997;89(7):1033-1041.
27. Zuvich RL, McCauley JL, Oksenberg JR, et al. Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet 2010;127(5):525-535.
28. Maier LM, Lowe CE, Cooper J, et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 2009;5(1):e1000322.
29. Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007;39(9):1074-1082.
30. Brand OJ, Lowe CE, Heward JM, et al. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf) 2007;66(4):508-512.
31. Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40(2):204-210.
32. Barton A, Thomson W, Ke X, et al. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat Genet 2008;40(10):1156-1159.
33. The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009;41(7):824-828.
34. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, et al. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 2008;40(12):1402-1403.
35. Jakkula E, Leppa V, Sulonen AM, et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet 2010;86(2):285-291.
36. International Multiple Sclerosis Genetics Consortium (IMSGC). Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. Hum Mol Genet 2010;19(5):953-962.
37. Hafler JP, Maier LM, Cooper JD, et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 2009;10(1):5-10.
38. Dardalhon V, Schubart AS, Reddy J, et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol 2005;175(3):1558-1565.
39. De Jager PL, Baecher-Allan C, Maier LM, et al. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A 2009;106(13):5264-5269.
40. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199(7):971-979.
41. Chitnis T, Khoury SJ. Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. J Allergy Clin Immunol 2003;112(5):837-849.
42. Sanna S, Pitzalis M, Zoledziewska M, et al. Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nat Genet 2010;42:495-497.
43. Schmitz ML. Activation of T cells: Releasing the brakes by proteolytic elimination of Cbl-b. Sci Signal 2009;2(76):pe38.
44. Chiang YJ, Kole HK, Brown K, et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 2000;403(6766):216-220.
45. Ban M, Goris A, Lorentzen AR, et al. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet 2009;17(10):1309-1313.
46. Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine 2009;47(3):149-156.
47. Liu X, Lee YS, Yu CR, Egwuagu CE. Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol 2008;180(9):6070- 6076.
48. Tamura T, Thotakura P, Tanaka TS, et al. Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages. Blood 2005;106(6):1938-1947.
49. Martinez A, Pittaluga S, Rudelius M, et al. Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: A novel germinal center marker. Am J Surg Pathol 2008;32(8):1190- 1200.
50. Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: A double-edged sword? Autoimmun Rev 2010;9(3):188-193.
51. Suvannavejh GC, Lee HO, Padilla J, et al. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol 2000;205(1):24-33.
52. Henderson RD, Bain CJ, Pender MP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci 2000;7(5):434-437.
53. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: A descriptive study. Lancet Neurol 2006;5(11):924-931.
54. Hunt KA, Zhernakova A, Turner G, et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008;40(4):395-402.
55. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359(7):1786-1801.
56. Cournu-Rebeix I, Genin E, Leray E, et al. HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis. Genes Immun 2008;9(6):570-574.
57. Okuda DT, Srinivasan R, Oksenberg JR, et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009;132(pt 1):250-259.
58. Sombekke MH, Lukas C, Crusius JB, et al. HLA-DRB1 1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol 2009;66(12):1531-1536.
59. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009;18(4):767-778.
60. DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007;104(52):20896- 20901.
61. Byun E, Caillier SJ, Montalban X, et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008;65(3):337-344.
62. Comabella M, Craig DW, Morcillo-Suarez C, et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009;66(8):972-978.
63. De Jager PL, Chibnik LB, Cui J, et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: A weighted genetic risk score. Lancet Neurol 2009;8(12):1111-1119.
64. Sawcer S, Ban M, Wason J, Dudbridge F. What role for genetics in the prediction of multiple sclerosis? Ann Neurol 2010;67(1):3-10.
65. Baranzini SE, Galwey NW, Wang J, et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet 2009;18(11):2078-2090.